Altre lingue MyMD Pharmaceuticals, Inc.

Azioni

MYMD

US62856X2018

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
2,5 ^USD	-0,79%		+4,17%	-67,79%

09/04	Wall Street si appresta ad aprire in leggero rialzo, mentre gli investitori attendono i dati sull'inflazione di mercoledì	MT
09/04	Gli investitori guardano ai dati sull'inflazione di mercoledì, mentre i futures statunitensi sono fermi martedì prima della campanella	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN	10/04
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04
Top Premarket Gainers	09/04
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	05/03
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	05/03
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	13/02
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	13/02
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Developing a first-in-class small molecule drug for inflammatory disease	09/11
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	20/10/23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain	19/10/23
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	19/10/23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023	05/10/23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023	04/10/23
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	04/10/23
MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from S&P Global BMI Index	18/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MyMD Pharmaceuticals, Inc.

Azioni

MYMD

US62856X2018

Altre lingue

Filtri